increas convict outlook beyond follow recent
investor meet attend ryan weispfen mark wilterd
reiter outperform increas price target
deliv strong organ sale growth perform last
three quarter compani rais guidanc fiscal organ revenu
growth rang previous manag focus
transit mdt averag weight growth exposur right
posit particip multipl multibillion-dollar market compani long-rang
plan sale growth target seem achiev us especi given strength
pipelin product slate launch next month highlight
initi divis start page recap tct comment begin page
free company-wid prioriti
gener free cash flow repres convers ratio
adjust inclus post-tax amort compar
entireti fiscal convers ratio made
meaning improv manag account receiv account
payabl meet manag emphas made focu
part corpor cultur start tie one-third annual incent
compens success achiev benchmark compani goal fiscal
remain see litig headwind dissip year
benefit program put place improv work capit
compani convers ratio target within next two three year
long-rang plan also intend return annual sharehold
fiscal long-rang plan
expect ep margin target achiev
despit modest earn dilut mzor acquisit maintain
fiscal adjust ep guidanc repres year-over-
year constant currenc growth recent rais previou rang
mdt target adjust ep growth long-rang plan period
believ doabl compani maintain fiscal oper margin guidanc
repres improv constant currenc basi
common erp system believ allow drive save futur
margin expans come sg effort close manag
back-offic function use share servic legal hr financ
compani pare back spend howev believ increas
 budget time still deliv margin target investor long-
rang plan call bp annual underli oper margin expans think
investor encourag manag revis strategi set expect
margin increas longer confin annual expans goal
laid former long-rang plan outlin june analyst day
pleas see page report import disclosur
outperform rate driven optimist outlook
sustain mid-single-digit top-lin growth trajectori combin mdt/cov
entiti combin cost synergi tax rate improv expect
new meet/exce goal grow adjust ep faster
revenu expect pipelin growth driver like becom focu investor
product contribut meaning first full year commerci
view new continu top-tier top- bottom-lin growth
perform medic devic space
on-going launch new product
resolut onyx
maintain de market share
us
stabil us spine
strong adopt corevalv us
return growth spine franchis
out-year top-lin growth acceler
market share loss
continu deterior spine
weak adopt trend new product
diversifi medic technolog servic solut compani presenc
countri combin entiti covidien
merger new oper four segment cardiac vascular group
minim invas therapi group diabet restor therapi group cardiac
vascular group segment manufactur market device-bas medic therapi
cardiac rhythm heart failur crhf coronari structur heart aortic
peripher vascular mitg focus advanc gener surgic technolog
diabet segment manufactur market device-bas medic therapi diabet
restor therapi group segment manufactur market device-bas medic
therapi spine neuromodul surgic technolog
cardiac vascular group
tavr within cvg mdt tavr busi grow faster ew last
quarter lot growth come europ evolut driver
perform well thank valv lower rate paravalvular leak perman
pace compani also realiz benefit europ cath lab manag servic
discuss comment mdt market share manag account
larger non-manag account overal breadth cvg product help
well sinc tavr still fulfil technolog need use
purchas manag project tavr busi continu grow
faster market indefinit expect pressur competitor includ new
ew product respect new entrant compani previous
referenc preced seen europ ew split major
market year leav combin competitor lotu impact
may greater valv come market earlier time
low pvl rate uniqu evolut sapien avail
bsx competit advantag due low pvl rate shrunk unlik stent tavr
complic procedur requir oper invest time learn thing like
particular deliveri system perform differ patient therefor new entrant may
struggl take meaning share amount market howev
think oblivi scenario low level share must come
somewher could pressur tavr unit risk approv could
come shortli lotu commerci fuel belief compani
may outgrow market could still see strong revenu growth contribut
structur heart divis tavr market confer next
spring low-risk data releas may show slight deceler grow
mid- high teen vs growth last year what unclear ew clinic
commun investor big boost low-risk approv
much increment growth bring
mitral regard mitral space mdt apollo trial intrepid mitral valv treat
first patient last octob contrast began pivot trial tendyn mitral
valv past juli repres two four major program address multi-
billion-dollar opportun commerci option next five year
new multi-billion dollar opportun pipelin start apollo
transpic approach transit transsept deliveri option without disrupt
trial enrol compani readi begin transsept deliveri late fiscal
estim trial take month total enrol patient mitral
market two three time larger tavr market anatomi
mitral valv present problem manufactur creat clinic risk potenti
opportun size offset challeng lastli regard repair side replace/
repair toolbox strategi mitral indic intern program
extern partnership evalu repair technolog compani firmli believ
replac work achiev good clinic outcom replac market
domin repair opportun
ask larg maintain share face competit
mr-safe high-pow launch histor cite traction sticki
gotten cath lab tyrx risk-shar model tyrx sold roughli per
pouch compani offer provid toward infect requir implant
replac tyrx use risk-shar program around inappropri
shock heart failur rehospit dcb among thing
also help retain share importantli tyrx initi implant
also address pain devic deep brain stimul pelvic health technolog
tangibl impact arrang compel instanc account
adopt tyrx program averag show double-digit growth increas use product
vs baselin also manag roughli cath ep lab across hospit
 devic share typic contract increas
threshold time among low-pow devic view posit favor due
micra drive share single-chamb market three time price
standard single-chamb pacer compani exclus opportun micra
sinc develop path abt nanostim devic unknown doesnt
immedi solut continu believ leadless pace
total single-chamb pm market time sinc there physician interest avoid potenti
problem associ pm pocket infect transven lead
potenti problem expens fix micra manag justifi sizabl price
premium patient respond favor micra well sinc newer technolog
option categori limit innov plan eventu launch two
addit version micra first due month sens atrial contract
pace ventricl dual chamber pm solut extend micra market opportun
de novo pm implant lastli pipelin contain
extravascular ev- one new multi-billion dollar opportun within
next year renal denerv repres anoth pipelin platform potenti
futur revenu contribut
rtg made histor run late post two best top-lin result ever
last two quarter attribut much success decis leav
invest busi head make respons resourc
alloc think behind strategi busi head closer
custom thu better understand custom need
recognit custom need proven tremend advantag make
 decis shift decentr decision-mak allow mdt take
bigger step innov compani previous made slight increment
improv product first implement cvg approach reach
rtg effect alreadi appar mdt recent quarterli perform would
indic revenu growth enabl rtg record best quarter
eight-year histori growth driven continu strength brain pain look
divis perform sequenti comp eas except brain
lag db contribut headwind futur quarter deceler seen
could signal share loss may acceler ahead new product launch like
aspir cathet discuss recent mdt overal market penetr
aspir stent reliev still way go progress get help
becom equal-opportun provid aspir retriev
allow custom buy product procedur requir
use neurovascular success product penetr flow divers stent
neuro access embol product lead growth brain franchis strong
momentum pain look continu three sub-seg franchis hit
stride recent contribut intelli also deliv boost growth
spinal cord stim drug pump neighborhood mid-teen growth last
quarter intervent pain seen posit result osteocool vertebroplasti
despit gener stagnant spine market confid posit believ
competit advantag first time decad leverag capit
equip look pull implant order custom compani
alreadi engag capit use manag also express excit
regard merger stealthstat navig platform mzor robot technolog
synergi two addit well o-arm imag system look final
pay debut stealthstat mzor collabor surgic system
launch nass today start take order januari recent address
acquisit mzor highlight spine sale grew
core busi sale combin sale spine-specif capit system
get report neurosurgeri lead compani believ final back offens
spine market
mitg stori gain momentum past quarter end sight
thank strong product pipelin continu benefit mdt relationship
mzor partnership mzor date back enabl compet
major player robot also provid compani platform
build success mi decis make mzor partnership perman
surpris investor acquisit line mdt long-
term goal build robot spine busi initi robot
aid focu world-wide leader mi look grow market
share space evidenc commit dedic largest bulk
resourc toward develop advanc surgic robot system obvious
establish player robot learn prepar enter
market isrg da vinci surgic system clearli found success hospit
well-receiv surgeon howev robot carri prohibit cost would-b
user prevent reach hospit price dynam like
signific factor still-limit penetr robot mi surgeri nearli
surgeri perform today open done use minim invas techniqu
less surgeri done robot believ grow market
develop surgic robot demonstr econom valu hospit
provid surgeon product feel confid use specif creat
surgic system incorpor exist product portfolio like
signia power stapler tri-stapl ligasur vessel seal dispos
product current drive growth mitg mani surgeon alreadi
use make easier integr full system overcom
price barrier plan make system cost-effect work
hospit make capit acquisit easier anoth way plan differenti
market approach oper larg enough scale
capac access mani market particularli em establish train center around
world alreadi train thousand surgeon china annual global presenc
allow train surgeon use system abroad make improv possibl
build market share goe follow success intern roll compani
believ make natur transit bring surgic system although
exact timelin regulatori approv announc full launch slate fiscal
meaning revenu contribut fiscal lastli mitg pipelin
contain portabl hemodialysi system one new multi-billion dollar
opportun within next year
diabet expect divis sale grow
although pump technolog exist year pump use among type
diabet still one-third penetr think continu innov support
multi-year growth pump market among diabet technolog manufactur
forefront industri effort integr cgm pump therapi
enabl deliveri insulin pump sensor tell pump
believ insur continu respond favor addit clinic data prove
overwhelm benefit pump cgm technolog initi went unit
safeti data show differ hypoglycemia claim patient
use mdt predict low-glucos suspend featur compar use non-mdt
technolog result favor prompt unit make compani prefer
pump vendor turn creat challeng competit pump enabl
gain market share compani hybrid close loop system keep
patient rang deliv insulin glucos high stop deliveri
glucos low activ user late august believ
futur enhanc autom continu reduc therapi burden
patient lead greater adopt also improv made term
afford pump usag sinc insur compani requir patient make
co-pay multi-thousand-dollar devic work insur lower
out-of-pocket cost patient base clinic data show pump save
insur money within cgm higher sensor attach rate sensor use
pump drive strong sale growth also creat bigger annuiti stream
help smooth revenu lumpi come
pump sale everi four five year sensor diagnost cost approxim dollar
per day yield per patient per year previous fewer one-third
pump patient use sensor two-third instal base use
sensor patient use older pump plan
launch advanc hybrid closed-loop within next month hybrid
patient need log theyr meal alert pump need insulin
bolu compani also work enhanc algorithm technolog person ai
chang base individu reaction insulin tailor therapi
close patient today formula approach that appli across
entir instal base launch mdt guardian connect progress well allow
compani take share billion stand-alone market howev lack dose
claim fda remov need sensor calibr via finger stick
fiscal year compani start clinic studi necessari submit dose claim
believ receiv claim sometim fiscal wed note fda
set higher bar sensor use close loop system make
us increment confid mdt abil secur dose claim lastli compani
acknowledg success abt libr type market especi given
low cost need start system libr patient may eventu
want true cgm includ guardian connect believ type devic market
fragment evalu differ option primarili focus guardian
connect
tct investor event voic enthusiasm two-year surtavi result
coapt suggest eluvia impact superfici femor arteri diseas
get treat may revolutionari hope surtavi evalu tavr
corevalv evolut vs open-heart surgeri savr intermediate-risk aortic
stenosi patient full two-year data set show rate all-caus mortal
disabl stroke tavr two year compar savr
tavr also demonstr statist signific differ mean aortic valv gradient
vs savr two year mm hg compar mm hg addit
tavr patient experienc statist signific lower rate stroke new onset
atrial fibril hospit discharg acut kidney injuri transfus meanwhil
savr patient fewer perman pacemak implant less aortic regurgit
compar tavr patient investor event monday cvg manag reiter
belief evolut repres step evolut compani hope
advantag lower stroke rate tavr shown surtavi made even
greater newer devic issu embol protect tavr say
intrigu concept watch area close compani embol protect
devic spiderfx indic peripher svg carotid applic hint
think new technolog may offer benefit bsx sentinel devic didnt commit
develop plan say continu assess need
coapt cvg manag spoke glowingli robust trial valu
establish benefit devic therapi function mr patient concept
believ directli appli on-going work intrepid mitral valv apollo
trial devic specif trial cvg manag said studi investig held
meet sunday night discuss near-term repercuss coapt could
progress investig insist still patient think viabl
tct event cvg manag
apollo trial ward potenti slowdown enrol importantli
continu access coapt formal fda approv yet apollo
enrol monitor close feel comfort plan
physician begin debat generaliz coapt result cvg manag
didnt offer specif timet introduc transsept deliveri apollo studi
say late calendar year earli next calendar year essenti match
late fiscal time compani provid previous lastli issu repair
vs replac comment coapt particularli help see reduc mr
favor effect outcom lead believ entir elimin mr via
replac therapi could yield even better result said compani continu
evalu repair option heard earlier meet manag final
respons question eluvia acknowledg substanti valu conduct
head-to-head trial peripher space suggest physician real-world
treatment protocol may slower shift would like sinc introduct
drug-coat balloon say greater rift ever leave-nothing-
behind propon use dcb sfa procedur open stent
sfa procedur compani see dcb use erod eluvia launch
next month especi given dcb traction long lesion longer stent pose
greater risk fractur long lesion mani interventionalist continu use
dcb spot stent focal lesion need bare metal stent like continu
strong player spot capac accord cvg manag also express
interest await two-year result imperi trial better judg durabl
eluvia outcom note majest trial support eluvia ce mark
show drop-off two year
although year-over-year revenu growth comparison challeng back
half fiscal year rel first half compani express confid
oper momentum experienc bode well strong
perform alreadi incorpor favor prior-year comparison also believ
manag continu temper expect comp set well
understood price target share move previous new
target deriv multipl appli forward year ep ebitda
forecast respect multipl still repres discount mdt large-cap
medic devic peer group consid stock setup attract compani
near-term catalyst hit tct class effect read coapt
data tmvr program strong updat nass week
spine divis host come parti integr stealthstat mazor
execut rais pt
compani report thomson eikon cowen compani
medtron plc revenu build mm fiscal year end april year end april y/i y/i ex-fx y/i y/i ex-fx y/i y/i ex-fx therapi y/i y/i ex-fx y/i develop y/i y/i ex-fx y/i y/i ex-fx y/i ex-fx impact impact cowen compani estim compani file transcript cowen
compani report thomson eikon cowen compani
medtron incom statement mm except per share y/i y/i cc good incom non-oper expens tax net dilut share y/i tax net y/i item tax net y/i cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
continu util pressur account organ play bigger
role health care deliveri competit dynam global potenti regulatori delay
reject failur devic clinic trial econom sensit price pressur
and/or weaken consum demand develop market econom and/or polit
uncertainti emerg market intellectu properti challeng
continu util pressur competit dynam global potenti
regulatori delay reject failur devic clinic trial econom sensit
price pressur and/or weaken demand develop market econom and/or
polit uncertainti emerg market electrophysiolog clinic commun deem
st jude medic durata lead safe effect yale independ review infus
biolog cite cancer promot effect fluctuat foreign exchang rate
